NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $41.67M rose 51.5% year over year, ahead of the +4.1% change in trailing-twelve-month research & development. Sequentially, it rose 11.1% from the prior quarter. Over 3 fiscal years it compounded at +17.8% a year.

Context

  • Research & development amounted to 630.3% of revenue in FY2025, up 298.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +51.5% holds above the trailing-twelve-month pace of +4.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$41.67M+11.1% QoQ
Last fiscal yearDec 2025
$141.83M-6.3% YoY
LTMJun 2026
$148.75M+4.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.5%——
1 year-6.3%——
3-year CAGR+17.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
141.83M USD
Year-over-year change
-6.3%
4-year CAGR
+48.7%

Research & Development vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.1% is the 6th highest of 9, against a peer median of +23.3%.
  • Research & development amounts to 2088.9% of revenue for NAMS, versus a peer median of 264.8%.
NAMS Competitors
Research & Development for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$509.32M USD+227.9%+85.3%—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$490.14M USD+154.4%+16.5%38.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M USD-3.9%+5.3%11118.8%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$148.75M USD+4.1%+17.8%2088.9%
SEPNSepterna, Inc.LTM Sep 2026$132.66M USD+56.0%—137.8%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$100.83M USD+9.7%-1.1%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M USD-9.9%+48.0%—
BIOABioAge Labs, Inc.LTM Mar 2026$83.27M USD+36.9%+34.3%807.2%
ATHEAlterity Therapeutics LimitedFY2025A$14.4M AUD-22.7%-0.8%264.8%
Peer median (excluding NAMS) —+23.3%+16.5%264.8%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.